

Raising the bar for data standardization:

How to ensure your submission data supports automated review process at FDA and PMDA?

Sergiy Sirichenko

PhUSE SDE, Foster City, CA

February 22, 2018




CDISC standards and their adaption

- › 1997 – CDISC started as a Volunteer group
- › 2005 – SDTM IG 3.1.1, Define-XML 1.0
- › 2008 – OpenCDISC
- › 2009 – SDTM IG 3.1.2, ADaM IG 1.0
- › 2011 – SEND IG 3.0
- › 2016 – Required by FDA for new studies
- › 2016 (2022) – Required by PMDA

Benefits of standards


- › Similarity across studies
- › Ease of integration
- › Re-use of code
- › Standardized tools
- › Automation
- › ...

Manual programming



- › Input data is not standardized
- › Data manipulation before reporting and analysis

Standardized tools




- › Input data is partially standardized
- › Manual configuration may be needed

Examples

- › MAED
 - › Subject, Treatment, Adverse Event term
 - › One record per AE

- › Liver Function Panel
 - › Lab results, normal ranges
 - › Default use of CDISC, but can be adjusted for non-standard structure and terms (SGOT instead of ASP)

Automated process



- › Automated input for standardized tools
- › High requirements for standardization

Automation relies on standards

- › Location of files
- › File names
- › Structure
- › Control Terminology
- › Expected content
- › Data quality

Example of wrong Normal Ranges

› Expected

LBTEST	LBSTRESN	LBSTNRHI	LBSTNRC
ALT	42	42	
AST	5	20	
BILI	28	38	

› Incorrect

LBTEST	LBSTRESN	LBSTNRHI	LBSTNRC
ALT	42		<42
AST	5		<20
BILI	28		<38

- › Data is present, but it was implemented incorrectly
- › Standard reporting tools will not produce results
- › Data manipulation is needed to run analysis
 - › LBSTNRHI is Num, LBSTNRC is Char variable

FDA definition for data quality


- › *“Quality data would therefore be defined as data that sufficiently support conclusions and interpretations equivalent to those derived from error-free data”*

Janet Woodcock, M.D., 1999

- › *“Study data validation helps to ensure that the study data are compliant, useful, and will support meaningful review and analysis”*

FDA TCG, 2017-10

Overview of the NDA/BLA Review Process and Major Steps for Completing the Review



Note: The timeline for review of NMEs/BLAs under PDUFA V's "Program" Review extends the *Conduct Review* Phase by two months. See Appendix A for a timeline diagram for PDUFA V.

Increasing demand for data quality

- › FDA goal is to make drugs available ASAP
- › Manual review process has lower expectations on data quality
 - › Often it's more quick for Reviewer to fix or work around issues rather than request fix from Sponsor
 - › Data review time is limited
 - › Data quality evaluation is difficult
- › Automation relies on high quality data
 - › Value of standard reporting and analysis for Reviewers increases demand for data quality
 - › Standardized data allows early evaluation and enforcement of data quality

PMDA example

- › Submission of data is few weeks before filing the application
- › Consultation meetings
- › Any Rejection issues (34 rules) must be fixed
- › Reconciliation of validation results and Sponsor's explanations


FDA has just started

- › Current 4 FDA Rejection rules are not enough
- › *“Trial Summary (TS) dataset must be included in every submission”*
 - › Machine-readable metadata about study start date to decide if study must be in CDISC?
 - › What about rules to ensure?
 - › Presence of this info
 - › Use of CDISC CT term for *Study Start Date*
 - › *“SSTDTC”* - SDTM
 - › *“STSTDTC”* - SEND
 - › ISO 8601 format for date

Errors by Application and Study

Potential Rejections


- Applications with At Least 1 Error
- Applications with No Errors



*70 Applications Assessed

Study Errors

- Studies With At Least 1 Error
- Studies With No Errors



*222 Studies Assessed

Automation of validation

- › Pinnacle 21 (P21) Community – desktop tool
- › P21 Enterprise – web-based application with centralized governance
- › FDA DataFit and PMDA P21 Enterprise – P21 Enterprise with additional automation for FDA/PMDA environments based on
 - › eCTD structure
 - › study metadata

Automation logic

- › Automation relies on standards
- › Validation is performed according metadata provided by Sponsor (correct or incorrect)
- › If study metadata is invalid or missing then some compensation actions are taken
 - › For example, the latest versions of standards or dictionaries will be utilized instead

eCTD issues

- › Data in incorrect folder is considered as missing
 - › 90xxxx\0000\m5\datasets\study-1\tabulations\sdtm – OK!
 - › 90xxxx\0000\m5\datasets\study-1\sdtm - incorrect
- › Files with non-standard or inconsistent names
 - › *define-study-1.xml* instead of *define.xml*
 - › Define.xml has a reference to “*blankcrf.pdf*”, but actual file is “*acrf.pdf*”
- › When submitting additional or modified datasets, an update of define.xml for the whole study data is needed

SDTM version in define.xml

- › P21C – manual input
- › P21E – pre-configured by project manager
- › DataFit – from define.xml file

```
def:StandardName="SDTM-IG"  
def:StandardVersion="3.2">
```

- › Example: study data utilized *SDTM IG 3.1.2*, but define.xml file has reference to *SDTM IG 3.1.3*
 - › Unexpected PMDA Reject notification
 - › Many false-positive and false-negative messages due to utilization of wrong configuration

Invalid or missing MedDRA version

- › DataFit uses define.xml file
 - › `<ExternalCodeList Dictionary="MedDRA" Version="19.0"/>`
- › If missing then the latest version of MedDRA is utilized
- › Incorrectly implemented (e.g., like *Comment* instead of *Dictionary*) MedDRA version means missing info
- › MedDRA version is utilized by some reporting tools
- › Missing decimal points in version is PMDA Rejection criteria
 - › “19” instead of “19.0”

https://www.cdisc.org/system/files/all/event/restricted/2017_Japan/Japan%202017_Session%206_Oda.pdf

Version of CDISC CT

- › Today there is no machine-readable info about CDISC Control Terminology

- › Waiting for Define-XML v2.1

- › DataFit utilizes the latest version of CDISC CT

- › 2011 – 104 Codelists

- › 2017 – 730 Codelists

- › Terms for NCI Code = C17988 are used inconsistently across codelists and versions:

Term	2011-07	2017-12
<i>U</i>	6	3
<i>UNK</i>	1	1
<i>UNKNOWN</i>	5	14

- › *U* -> *UNKNOWN* in SDTM CT 2014-03-28 for 3 non-extensible codelists ENRTPT, STENRF and STRTPT

Other examples Janus CTR

- › None of Data Integrity checks are *Rejection* now
 - › Missing subjects in DM -> fail to upload study data
- › Upload process relies on *def:Class* in define.xml
- › Trial Summary data is critical for CTR search

<https://www.fda.gov/downloads/ForIndustry/DataStandards/StudyDataStandards/UCM442108.pdf>

Summary

- › The automation of regulatory review is a game changing event
- › Standardized high quality study data is critical for automation
- › Expect new Rejection rules and their enforcement from Regulatory Agencies